Cardiovascular complications and increased levels of circulating modified low density lipoprotein in HIV patients and patients with lipodystrophy

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 1, 2004, Pages 119-122

  Ronchini, K R O M ^a   Duarte, A J S ^a   Casseb, J S R ^a   Gidlund, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Coronary artery disease; HIV; Lipodystrophy; Modified low density lipoprotein; Oxidized LDL

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBODY; BIOLOGICAL MARKER; CD4 ANTIGEN; LOW DENSITY LIPOPROTEIN;

ANTIBODY TITER; ARTICLE; BODY DISTRIBUTION; BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MARKER; FOAM CELL; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE STATUS; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; PATHOGENESIS; PROTEIN MODIFICATION; T LYMPHOCYTE; TISSUE LEVEL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1242284668     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000100016     Document Type: Article

References (19)

1. Louie JK, Hsu LC, Osmond DH, Katz MH & Schwarcz SK (2002). Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. Journal of Infectious Diseases, 186: 1023-1027.
2. Meng Q, Lima JA, Lai H et al. (2002). Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. American Heart Journal, 144: 642-648
3. Esterbauer H, Gebicki J, Puhl H & Jurgens G (1992). The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine, 13: 341-390.
4. Hevonoja T, Pentikainen MO, Hyvonen MT, Kovanen PT & AlaKorpela M (2000). Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochimica et Biophysica Acta, 1488: 189-210.
5. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H & Gidlund M (1990). Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proceedings of the National Academy of Sciences, USA, 87: 904-908.
6. Witztum JL & Steinberg D (2001). The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends in Cardiovascular Medicine, 11: 93-102.
7. Hansson GK (2002). Vaccination against atherosclerosis: science or fiction? Circulation, 106: 1599-1601.
8. Shoenfeld Y, Sherer Y & Harats D (2001). Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends in Immunology, 22: 293-295.
9. Svensjo E, Boschcov P, Ketelhuth DF, Jancar S & Gidlund M (2003). Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflammation Research, 52: 215-220.
10. Carvalho MD, Harada LM, Gidlund M, Ketelhuth DF, Boschcov P & Quintão EC (2002). Macrophages take up triacylglycerol-rich emulsions at a faster rate upon co-incubation with native and modified LDL: An investigation on the role of natural chylomicrons in atherosclerosis. Journal of Cellular Biochemistry, 84: 309-323.
11. Zaratin A, Gidlund M, Boschcov P, Castilho L & de Faria EC (2002). Antibodies against oxidized low-density lipoprotein in normolipidemic smokers. American Journal of Cardiology, 90: 651-653.
12. Uint L, Gebara OCE, Pinto LB, Wajngarten M, Boschcov P, da Luz PL & Gidlund M (2003). Hormone replacement therapy increases levels of antibodies against heat shock protein 65 and certain species of oxidized low density lipoprotein. Brazilian Journal of Medical and Biological Research, 36: 491-494.
13. Cazita PM, Berti JA, Aoki C, Gidlund M, Harada LM, Nunes VS, Quintao EC & Oliveira HC (2003). Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. Journal of Lipid Research, 44: 33-40.
14. Wu R, de Faire U, Lemne C, Witztum JL & Frostegard J (1999). Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension, 33: 53-59.
15. Shoenfeld Y, Harats D & George J (2000). Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. Journal of Autoimmunity, 15: 199-202.
16. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T & Morii H (2000). Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis, 148: 171-177.
17. Damasceno NR, Goto H, Rodrigues FM, Dias CT, Okawabata FS, Abdalla DS & Gidlund M (2000). Soy protein isolate reduces the oxidizability of LDL and the generation of oxidized LDL autoantibodies in rabbits with diet-induced atherosclerosis. Journal of Nutrition, 130: 2641-2647.
18. Carr A (2000). HIV protease inhibitor-related lipodystrophy syndrome. Clinical Infectious Diseases, 30 (Suppl II): 135-142.
19. Christeff N, Melchior JC, Truchis P, Perrone C, Nunez EA & Gougeon M-L (1999). Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Nutrition, 15: 534-539.